Innovation, drug discovery

Natural products represent an unparalleled source of molecular diversity for innovative drug discovery. In the pharmaceutical industry, there is an urgent need to identify novel lead structures for effective drug development in many therapeutic areas. It is likely that natural halogen compounds will continue to contribute leads to future research. 

Eli-Lilly s Open Innovation Drug Discovery Global https //openinnovationJilly.com/dd/... 

Marina Virgin, Carmen Almansa, and Fernando L Cavalcanti, Innovation Drug Discovery, Palau Pharma S.A, Av Cami reial 51-57, E-08184 Palau-Solita i Plegamans, Spain, Fax +34 938646606... 

Schmid EF, Smith DA. Is declining innovation in the pharmaceutical industry a myth Drug Discovery Today 2005 10 1031-9. 

Andersen Consulting (1997) Re-inventing drug discovery the quest for innovation and productivity. Anderson Consulting, London... 

ChemOvation Ltd., founded in 1998, focuses on providing an integrated drug discovery support service via collaborative programs, and the manufacture of innovative compound libraries. Apart from that, their range of services includes chemistry development, automated parallel synthesis, scale-up, process development, and screening. 

The identification of compounds with a desired property is a central pursuit in science. In the field of drug discovery combinatorial chemistry has played an increasingly important role for identification and optimization of drug leads which target therapeutically important biomolecules. For the successful implementation of combinatorial methods, new and innovative synthesis methods have been developed. Additionally, novel conceptual approaches to the design of compounds have been pursued to more efficiently generate libraries of small molecules. 

Drews, J. Innovation deficit revisited reflections on the productivity of pharmaceutical R D. Drug Discovery Today 1998, 3, 491-494. 

The business model of the innovative pharmaceutical industry is to transform the results of basic medical research into products that provide health benefits to the patient. This model is characterized by a high risk of failure in the development of new products, coupled with the benefit of market exclusivity for a number of years if a product can be successfully developed and is approved by the regulatory agencies. Only very few chemical entities complete the development process from drug discovery to a commercial product. But those products that do reach the marketplace have to yield sufficient financial rewards to assure that the... 

---